Abstract
The development of diabetic nephropathy (DN) could be promoted by the occurrence of tubulointerstitial fibrosis (TIF), which has a close relationship with mitochondrial dysfunction of renal tubular epithelial cells (RTECs). As a key regulator of metabolic homeostasis, Yin Yang 1 (YY1) plays an important role not only in regulating the fibrosis process but also in maintaining the mitochondrial function of pancreatic β-cells. However, it was not clear whether YY1 participated in maintaining mitochondrial function of RTECs in early DN-associated TIF. In this study, we dynamically detected mitochondrial functions and protein expression of YY1 in db/db mice and high glucose (HG)-cultured HK-2 cells. Our results showed that comparing with the occurrence of TIF, the emergence of mitochondrial dysfunction of RTECs was an earlier even, besides the up-regulated and nuclear translocated YY1. Correlation analysis showed YY1 expressions were negatively associated with PGC-1α in vitro and in vivo. Further mechanism research demonstrated the formation of mTOR-YY1 heterodimer induced by HG up-regulated YY1, the nuclear translocation of which inactivated PGC-1α by binding to the PGC-1α promoter. Overexpression of YY1 induced mitochondrial dysfunctions in normal glucose-cultured HK-2 cells and 8-weeks-old db/m mice. While, dysfunctional mitochondria induced by HG could be improved by knockdown of YY1. Finally, downregulation of YY1 could retard the progression of TIF by preventing mitochondrial functions, resulting in the improvement of epithelial-mesenchymal transition (EMT) in early DN. These findings suggested that YY1 was a novel regulator of mitochondrial function of RTECs and contributed to the occurrence of early DN-associated TIF.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
Data Availability
Not applicable.
Data Availability
The data and material used and/or analyzed during the current study are available from the corresponding authors on reasonable request.
References
Alyaseer A, de Lima M, Braga TT. The Role of NLRP3 Inflammasome activation in the epithelial to mesenchymal transition process during the fibrosis. Front Immunol. 2020;11:883. https://doi.org/10.3389/fimmu.2020.00883.
An P, Wei LL, Zhao S, Sverdlov DY, Vaid KA, Miyamoto M, Kuramitsu K, Lai M, Popov YV. Hepatocyte mitochondria-derived danger signals directly activate hepatic stellate cells and drive progression of liver fibrosis. Nat Commun. 2020;11(1):2362. https://doi.org/10.1038/s41467-020-16092-0.
Atchison M, Basu A, Zaprazna K, Papasani M. Mechanisms of Yin Yang 1 in oncogenesis: the importance of indirect effects. Crit Rev Oncog. 2011;16(3–4):143–61. https://doi.org/10.1615/critrevoncog.v16.i3-4.20.
Ayanga BA, Badal SS, Wang Y, Galvan DL, Chang BH, Schumacker PT, Danesh FR. Dynamin-related protein 1 deficiency improves mitochondrial fitness and protects against progression of diabetic nephropathy. J Am Soc Nephrol. 2016;27(9):2733–47. https://doi.org/10.1681/ASN.2015101096.
Balzer MS. Molecular pathways in peritoneal fibrosis. Cellular signalling. 2020;75:109778. https://doi.org/10.1016/j.cellsig.2020.109778.
Butow RA, Avadhani NG. Mitochondrial signaling: the retrograde response. Mol Cell. 2004;14(1):1–15. https://doi.org/10.1016/s1097-2765(04)00179-0.
Chatterjee R, Chatterjee J. ROS and oncogenesis with special reference to EMT and stemness. European journal of cell biology. 2020;99(2–3):151073. https://doi.org/10.1016/j.ejcb.2020.151073.
Chen F, Sun H, Zhao Y, Wang H. YY1 in cell differentiation and tissue development. Crit Rev Oncog. 2017;22(1–2):131–41. https://doi.org/10.1615/CritRevOncog.2017021311.
Chen F, Zhou J, Li Y, Zhao Y, Yuan J, Cao Y, Wang L, Zhang Z, Zhang B, Wang CC, Cheung TH, Wu Z, Wong CC, Sun H, Wang H. YY1 regulates skeletal muscle regeneration through controlling metabolic reprogramming of satellite cells. The EMBO journal. 2019;38(10):e99727. https://doi.org/10.15252/embj.201899727.
Chen YJ, Kong L, Tang ZZ, Zhang YM, Liu Y, Wang TY, Liu YW. Hesperetin ameliorates diabetic nephropathy in rats by activating Nrf2/ARE/glyoxalase 1 pathway. Biomed Pharmacother=Biomedecine Pharmacotherapie. 2019;111:1166–75. https://doi.org/10.1016/j.biopha.2019.01.030.
Chung KW, Dhillon P, Huang S, Sheng X, Shrestha R, Qiu C, Kaufman BA, Park J, Pei L, Baur J, Palmer M, Susztak K. Mitochondrial damage and activation of the STING pathway lead to renal inflammation and fibrosis. Cell Metab. 2019;30(4):784-799.e5. https://doi.org/10.1016/j.cmet.2019.08.003.
Cooper ME, Gilbert RE, Epstein M. Pathophysiology of diabetic nephropathy. Metab: Clin Exp. 1998;47(12 Suppl 1):3–6. https://doi.org/10.1016/s0026-0495(98)90362-6.
Cunningham JT, Rodgers JT, Arlow DH, Vazquez F, Mootha VK, Puigserver P. mTOR controls mitochondrial oxidative function through a YY1-PGC-1alpha transcriptional complex. Nature. 2007;450(7170):736–40. https://doi.org/10.1038/nature06322.
Du L, Qian X, Li Y, Li XZ, He LL, Xu L, Liu YQ, Li CC, Ma P, Shu FL, Lu Q, Yin XX. Sirt1 inhibits renal tubular cell epithelial-mesenchymal transition through YY1 deacetylation in diabetic nephropathy. Acta Pharmacol Sin. 2021;42(2):242–51. https://doi.org/10.1038/s41401-020-0450-2.
Forbes JM, Thorburn DR. Mitochondrial dysfunction in diabetic kidney disease. Nat Rev Nephrol. 2018;14(5):291–312. https://doi.org/10.1038/nrneph.2018.9.
Galvan DL, Green NH, Danesh FR. The hallmarks of mitochondrial dysfunction in chronic kidney disease. Kidney Int. 2017;92(5):1051–7. https://doi.org/10.1016/j.kint.2017.05.034.
Gao P, Yang L, Gui D, Zhang J, Han J, Wang J, Wang N, Lu J, Chen S, Hou L, Sun H, Xie L, Zhou J, Peng C, Lu Y, Peng X, Wang C, Miao J, Ozcan U, Huang Y, Jia W, Liu J. Yin Yang 1 protein ameliorates diabetic nephropathy pathology through transcriptional repression of TGFβ1. Sci Transl Med. 2019;11(510):eaaw2050.
Gibb AA, Lazaropoulos MP, Elrod JW. Myofibroblasts and fibrosis: mitochondrial and metabolic control of cellular differentiation. Circ Res. 2020;127(3):427–47. https://doi.org/10.1161/CIRCRESAHA.120.316958.
Gilbert RE, Cooper ME. The tubulointerstitium in progressive diabetic kidney disease: more than an aftermath of glomerular injury? Kidney Int. 1999;56(5):1627–37. https://doi.org/10.1046/j.1523-1755.1999.00721.x.
Gordon S, Akopyan G, Garban H, Bonavida B. Transcription factor YY1: structure, function, and therapeutic implications in cancer biology. Oncogene. 2006;25(8):1125–42. https://doi.org/10.1038/sj.onc.1209080.
Guerra F, Guaragnella N, Arbini AA, Bucci C, Giannattasio S, Moro L. Mitochondrial dysfunction: a novel potential driver of epithelial-to-mesenchymal transition in cancer. Front Oncol. 2017;7:295. https://doi.org/10.3389/fonc.2017.00295.
Guha M, Tang W, Sondheimer N, Avadhani NG. Role of calcineurin, hnRNPA2 and Akt in mitochondrial respiratory stress-mediated transcription activation of nuclear gene targets. Biochem Biophys Acta. 2010;1797(6–7):1055–65. https://doi.org/10.1016/j.bbabio.2010.02.008.
Guha M, Srinivasan S, Ruthel G, Kashina AK, Carstens RP, Mendoza A, Khanna C, Van Winkle T, Avadhani NG. Mitochondrial retrograde signaling induces epithelial-mesenchymal transition and generates breast cancer stem cells. Oncogene. 2014;33(45):5238–50. https://doi.org/10.1038/onc.2013.467.
Guo M, Liu D, Sha Q, Geng H, Liang J, Tang D. Succinic acid enhanced quantitative determination of blood modified nucleosides in the development of diabetic nephropathy based on hydrophilic interaction liquid chromatography mass spectrometry. J Pharm Biomed Anal. 2019;164:309–16. https://doi.org/10.1016/j.jpba.2018.10.042.
Healy E, Brady HR. Role of tubule epithelial cells in the pathogenesis of tubulointerstitial fibrosis induced by glomerular disease. Curr Opin Nephrol Hypertens. 1998;7(5):525–30. https://doi.org/10.1097/00041552-199809000-00007.
Higgins GC, Coughlan MT. Mitochondrial dysfunction and mitophagy: the beginning and end to diabetic nephropathy? Br J Pharmacol. 2014;171(8):1917–42. https://doi.org/10.1111/bph.12503.
Ishii K, Kobayashi H, Taguchi K, Guan N, Li A, Tong C, Davidoff O, Tran PV, Sharma M, Chandel NS, Kapp ME, Fogo AB, Brooks CR, Haase VH. Kidney epithelial targeted mitochondrial transcription factor A deficiency results in progressive mitochondrial depletion associated with severe cystic disease. Kidney Int. 2021;99(3):657–70. https://doi.org/10.1016/j.kint.2020.10.013.
Jiang N, Zhao H, Han Y, Li L, Xiong S, Zeng L, Xiao Y, Wei L, Xiong X, Gao P, Yang M, Liu Y, Sun L. HIF-1α ameliorates tubular injury in diabetic nephropathy via HO-1-mediated control of mitochondrial dynamics. Cell Prolif. 2020;53(11):e12909. https://doi.org/10.1111/cpr.12909.
Kaneda K, Sakata N, Takebayashi S. Mitochondrial enlargement and basement membrane thickening of renal proximal tubules, possible initiators of microalbuminuria in non-insulin-dependent diabetics (NIDDM). Acta Pathol Jpn. 1992;42(11):793–9. https://doi.org/10.1111/j.1440-1827.1992.tb01880.x.
Kang HM, Ahn SH, Choi P, Ko YA, Han SH, Chinga F, Park AS, Tao J, Sharma K, Pullman J, Bottinger EP, Goldberg IJ, Susztak K. Defective fatty acid oxidation in renal tubular epithelial cells has a key role in kidney fibrosis development. Nat Med. 2015;21(1):37–46. https://doi.org/10.1038/nm.3762.
Kim K, Lee EY. Excessively enlarged mitochondria in the kidneys of diabetic nephropathy. Antioxidants (basel, Switzerland). 2021;10(5):741. https://doi.org/10.3390/antiox10050741.
Kitada M, Ogura Y, Koya D. Rodent models of diabetic nephropathy: their utility and limitations. Int J Nephrol Renov Dis. 2016;9:279–90. https://doi.org/10.2147/IJNRD.S103784.
Kubo E, Shibata T, Singh DP, Sasaki H. Roles of TGF β and FGF signals in the lens: tropomyosin regulation for posterior capsule opacity. Int J Mol Sci. 2018;19(10):3093. https://doi.org/10.3390/ijms19103093.
Lei D, Chengcheng L, Xuan Q, Yibing C, Lei W, Hao Y, Xizhi L, Yuan L, Xiaoxing Y, Qian L. Quercetin inhibited mesangial cell proliferation of early diabetic nephropathy through the Hippo pathway. Pharmacol Res. 2019;146:104320. https://doi.org/10.1016/j.phrs.2019.104320.
Li Y, Kasim V, Yan X, Li L, Meliala ITS, Huang C, Li Z, Lei K, Song G, Zheng X, Wu S. Yin Yang 1 facilitates hepatocellular carcinoma cell lipid metabolism and tumor progression by inhibiting PGC-1β-induced fatty acid oxidation. Theranostics. 2019;9(25):7599–615.
Li X, Pan J, Li H, Li G, Liu X, Liu B, He Z, Peng Z, Zhang H, Li Y, Xiang X, Chai X, Yuan Y, Zheng P, Liu F, Zhang D. DsbA-L mediated renal tubulointerstitial fibrosis in UUO mice. Nat Commun. 2020;11(1):4467. https://doi.org/10.1038/s41467-020-18304-z.
Liu YW, Hao YC, Chen YJ, Yin SY, Zhang MY, Kong L, Wang TY. Protective effects of sarsasapogenin against early stage of diabetic nephropathy in rats. Phytother Res: PTR. 2018;32(8):1574–82. https://doi.org/10.1002/ptr.6088.
Liu Y, Tang ZZ, Zhang YM, Kong L, Xiao WF, Ma TF, Liu YW. Thrombin/PAR-1 activation induces endothelial damages via NLRP1 inflammasome in gestational diabetes. Biochem Pharmacol. 2020;175:113849. https://doi.org/10.1016/j.bcp.2020.113849.
Lu Y, Ma Z, Zhang Z, Xiong X, Wang X, Zhang H, Shi G, Xia X, Ning G, Li X. Yin Yang 1 promotes hepatic steatosis through repression of farnesoid X receptor in obese mice. Gut. 2014;63(1):170–8. https://doi.org/10.1136/gutjnl-2012-303150.
Lu Q, Ji XJ, Zhou YX, Yao XQ, Liu YQ, Zhang F, Yin XX. Quercetin inhibits the mTORC1/p70S6K signaling-mediated renal tubular epithelial-mesenchymal transition and renal fibrosis in diabetic nephropathy. Pharmacol Res. 2015;99:237–47. https://doi.org/10.1016/j.phrs.2015.06.006.
Lu Q, Chen YB, Yang H, Wang WW, Li CC, Wang L, Wang J, Du L, Yin XX. Inactivation of TSC1 promotes epithelial-mesenchymal transition of renal tubular epithelial cells in mouse diabetic nephropathy. Acta Pharmacol Sin. 2019;40(12):1555–67. https://doi.org/10.1038/s41401-019-0244-6.
Lu Q, Wang WW, Zhang MZ, Ma ZX, Qiu XR, Shen M, Yin XX. ROS induces epithelial-mesenchymal transition via the TGF-β1/PI3K/Akt/mTOR pathway in diabetic nephropathy. Exp Ther Med. 2019;17(1):835–46. https://doi.org/10.3892/etm.2018.7014.
Mohsen M, Elberry AA, Mohamed Rabea A, Abdelrahim M, Hussein R. Recent therapeutic targets in diabetic nephropathy. Int J Clin Pract. 2021;e14650. Adv Online Publication. https://doi.org/10.1111/ijcp.14650
Nandi S, Liang G, Sindhava V, Angireddy R, Basu A, Banerjee S, Hodawadekar S, Zhang Y, Avadhani NG, Sen R, Atchison ML. YY1 control of mitochondrial-related genes does not account for regulation of immunoglobulin class switch recombination in mice. Eur J Immunol. 2020;50(6):822–38. https://doi.org/10.1002/eji.201948385.
Nangaku M, Wanner C. Not only incretins for diabetic kidney disease-beneficial effects by DPP-4 inhibitors. Kidney Int. 2021;99(2):318–22. https://doi.org/10.1016/j.kint.2020.08.037.
Nath KA. Tubulointerstitial changes as a major determinant in the progression of renal damage. Am J Kidney Dis. 1992;20(1):1–17. https://doi.org/10.1016/s0272-6386(12)80312-x.
Qi H, Casalena G, Shi S, Yu L, Ebefors K, Sun Y, Zhang W, D’Agati V, Schlondorff D, Haraldsson B, Böttinger E, Daehn I. Glomerular endothelial mitochondrial dysfunction is essential and characteristic of diabetic kidney disease susceptibility. Diabetes. 2017;66(3):763–78. https://doi.org/10.2337/db16-0695.
Qi W, Keenan HA, Li Q, Ishikado A, Kannt A, Sadowski T, Yorek MA, Wu IH, Lockhart S, Coppey LJ, Pfenninger A, Liew CW, Qiang G, Burkart AM, Hastings S, Pober D, Cahill C, Niewczas MA, Israelsen WJ, Tinsley L, … King GL. Pyruvate kinase M2 activation may protect against the progression of diabetic glomerular pathology and mitochondrial dysfunction. Nature Med. 2017b;23(6):753–762. https://doi.org/10.1038/nm.4328
Saxena S, Mathur A, Kakkar P. Critical role of mitochondrial dysfunction and impaired mitophagy in diabetic nephropathy. J Cell Physiol. 2019;234(11):19223–36. https://doi.org/10.1002/jcp.28712.
Sharma K. Mitochondrial dysfunction in the diabetic kidney. Adv Exp Med Biol. 2017;982:553–62. https://doi.org/10.1007/978-3-319-55330-6_28.
Sharma K, McCue P, Dunn SR. Diabetic kidney disease in the db/db mouse. Am J Physiol Renal Physiol. 2003;284(6):F1138–44. https://doi.org/10.1152/ajprenal.00315.2002.
Song D, Yang Q, Jiang X, Shan A, Nan J, Lei Y, Ji H, Di W, Yang T, Wang T, Wang W, Ning G, Cao Y. YY1 deficiency in β-cells leads to mitochondrial dysfunction and diabetes in mice. Metab: Clin Exp. 2020;112:154353. https://doi.org/10.1016/j.metabol.2020.154353 Advance online publication
Srinivasan S, Guha M, Kashina A, Avadhani NG. Mitochondrial dysfunction and mitochondrial dynamics-the cancer connection. Biochim Biophys Acta. 2017;1858(8):602–14. https://doi.org/10.1016/j.bbabio.2017.01.004.
Tang ZZ, Zhang YM, Zheng T, Huang TT, Ma TF, Liu YW. Sarsasapogenin alleviates diabetic nephropathy through suppression of chronic inflammation by down-regulating PAR-1: in vivo and in vitro study. Phytomed: Int J Phytother Phytopharmacol. 2020;78:153314. https://doi.org/10.1016/j.phymed.2020.153314.
Thomas MJ, Seto E. Unlocking the mechanisms of transcription factor YY1: are chromatin modifying enzymes the key? Gene. 1999;236(2):197–208. https://doi.org/10.1016/s0378-1119(99)00261-9.
Vallon V, Thomson SC. The tubular hypothesis of nephron filtration and diabetic kidney disease. Nat Rev Nephrol. 2020;16(6):317–36. https://doi.org/10.1038/s41581-020-0256-y.
Verdeguer F, Soustek MS, Hatting M, Blättler SM, McDonald D, Barrow JJ, Puigserver P. Brown adipose YY1 deficiency activates expression of secreted proteins linked to energy expenditure and prevents diet-induced obesity. Mol Cell Biol. 2015;36(1):184–96. https://doi.org/10.1128/MCB.00722-15.
Wang L, Du Y, Xu BJ, Deng X, Liu QH, Zhong QQ, Wang CX, Ji S, Guo MZ, Tang DQ. Metabolomics study of metabolic changes in renal cells in response to high-glucose exposure based on liquid or gas chromatography coupled with mass spectrometry. Front Pharmacol. 2019;10:928. https://doi.org/10.3389/fphar.2019.00928.
Wang R, Qiu Z, Wang G, Hu Q, Shi N, Zhang Z, Wu Y, Zhou C. Quercetin attenuates diabetic neuropathic pain by inhibiting mTOR/p70S6K pathway-mediated changes of synaptic morphology and synaptic protein levels in spinal dorsal horn of db/db mice. Eur J Pharmacol. 2020;882:173266. https://doi.org/10.1016/j.ejphar.2020.173266.
Wei PZ, Szeto CC. Mitochondrial dysfunction in diabetic kidney disease. Clin Chim Acta; Int J Clin Chem. 2019;496:108–116. https://doi.org/10.1016/j.cca.2019.07.005
Xu J, Deng Y, Wang Y, Sun X, Chen S, Fu G. SPAG5-AS1 inhibited autophagy and aggravated apoptosis of podocytes via SPAG5/AKT/mTOR pathway. Cell Prolif. 2020;53(2):e12738. https://doi.org/10.1111/cpr.12738.
Xu BH, Sheng J, You YK, Huang XR, Ma R, Wang Q, Lan HY. Deletion of Smad3 prevents renal fibrosis and inflammation in type 2 diabetic nephropathy. Metab: Clin Exp. 2020a;103:154013. https://doi.org/10.1016/j.metabol.2019.154013
Yang SK, Li AM, Han YC, Peng CH, Song N, Yang M, Zhan M, Zeng LF, Song PA, Zhang W, Tang SQ, Zhang H. Mitochondria-targeted peptide SS31 attenuates renal tubulointerstitial injury via inhibiting mitochondrial fission in diabetic mice. Oxid Med Cell Longev. 2019;2019:2346580. https://doi.org/10.1155/2019/2346580.
Yang P, Huang T, Xu G. The novel mineralocorticoid receptor antagonist finerenone in diabetic kidney disease: progress and challenges. Metab: Clin Exp. 2016;65(9):1342–1349. https://doi.org/10.1016/j.metabol.2016.06.001
Yang T, Shu F, Yang H, Heng C, Zhou Y, Chen Y, Qian X, Du L, Zhu X, Lu Q, Yin X. YY1: a novel therapeutic target for diabetic nephropathy orchestrated renal fibrosis. Metab: Clin Exp. 2019b;96:33–45. https://doi.org/10.1016/j.metabol.2019.04.013
Yang T, Heng C, Zhou Y, Hu Y, Chen S, Wang H, Yang H, Jiang Z, Qian S, Wang Y, Wang J, Zhu X, Du L, Yin X, Lu Q. Targeting mammalian serine/threonine-protein kinase 4 through yes-associated protein/TEA domain transcription factor-mediated epithelial-mesenchymal transition ameliorates diabetic nephropathy orchestrated renal fibrosis. Metab: Clin Exp. 2020;108:154258. https://doi.org/10.1016/j.metabol.2020.154258
Yuan Y, Chen Y, Zhang P, Huang S, Zhu C, Ding G, Liu B, Yang T, Zhang A. Mitochondrial dysfunction accounts for aldosterone-induced epithelial-to-mesenchymal transition of renal proximal tubular epithelial cells. Free Radical Biol Med. 2012;53(1):30–43. https://doi.org/10.1016/j.freeradbiomed.2012.03.015.
Yuan X, Chen J, Cheng Q, Zhao Y, Zhang P, Shao X, Bi Y, Shi X, Ding Y, Sun X, Xue B. Hepatic expression of Yin Yang 1 (YY1) is associated with the non-alcoholic fatty liver disease (NAFLD) progression in patients undergoing bariatric surgery. BMC Gastroenterol. 2018;18(1):147. https://doi.org/10.1186/s12876-018-0871-2.
Zhang L, Zhang Y, Chang X, Zhang X. Imbalance in mitochondrial dynamics induced by low PGC-1α expression contributes to hepatocyte EMT and liver fibrosis. Cell Death Dis. 2020;11(4):226. https://doi.org/10.1038/s41419-020-2429-9.
Zhou D, Zhou M, Wang Z, Fu Y, Jia M, Wang X, Liu M, Zhang Y, Sun Y, Lu Y, Tang W, Yi F. PGRN acts as a novel regulator of mitochondrial homeostasis by facilitating mitophagy and mitochondrial biogenesis to prevent podocyte injury in diabetic nephropathy. Cell Death Dis. 2019;10(7):524. https://doi.org/10.1038/s41419-019-1754-3.
Acknowledgements
We thank Prof. Zhenzhou Jiang from China Pharmaceutical University for the article’s structural configuration.
Funding
The work was supported by the National Natural Science Foundation of China (81973377, 81903689, and 82073906), the Key Natural Science Foundation of Jiangsu Higher Education Institutions of China (19KJA460008 and 19KJB350006), Priority Academic Program Development of Jiangsu Higher Education Institutions (PAPD), the initializing fund of Xuzhou Medical University (D2018011), and Postgraduate Research Practice Innovation Program of Jiangsu Province (No. KYCX21-2733, KYCX21-2735, and KYCX21-2736).
Author information
Authors and Affiliations
Contributions
The experiments of this work were designed by Qian Lu, Xiaoxing Yin, and Tingting Yang. The experiments were performed by Yinlu Hu, Shangxiu Chen, Lin Li, and Fanglin Shu. Tingting Yang and Yinlu Hu analyzed the data and wrote the manuscript. Tingting Yang, Yinlu Hu, and Sitong Qian edited of the figures and tables. Tingting Yang, Qian Lu, and Xiaoxing Yin reviewed the manuscript. The rest of the authors either supplied reagent or helped in treatments to animal and cells.
Corresponding authors
Ethics declarations
Ethical approval and consent to participate
This study was approved and supervised by the animal ethics committee of the Animal Ethics Committee of Xuzhou Medical University and in accordance with the regulations for the administration of affairs concerning experimental animals (Ministry of Science and Technology, China).
Human ethics
Not applicable.
Consent for publication
Not applicable.
Competing interests
The authors declare no competing interests.
Additional information
Publisher's note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Tingting Yang and Yinlu Hu equally contributed to this work.
Rights and permissions
Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.
About this article
Cite this article
Yang, T., Hu, Y., Chen, S. et al. Correction to: YY1 inactivated transcription co‐regulator PGC‐1α to promote mitochondrial dysfunction of early diabetic nephropathy‐associated tubulointerstitial fibrosis. Cell Biol Toxicol 39, 2787–2792 (2023). https://doi.org/10.1007/s10565-023-09802-z
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10565-023-09802-z